Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic strategy for managing metabolic conditions. These naturally occurring molecules are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon release. GLP-1 peptides possess promising therapeutic results in treating type 2